<DOC>
	<DOCNO>NCT02891603</DOCNO>
	<brief_summary>The purpose study examine new approach prevent serious problem transplant call graft vs. host disease ( abbreviated GVHD ) . This single-arm , phase I/II , study Pacritinib Sirolimus Tacrolimus ( PAC/SIR/TAC ) prevention acute GVHD match related unrelated allogeneic hematopoietic cell transplantation ( alloHCT ) .</brief_summary>
	<brief_title>A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression</brief_title>
	<detailed_description>GVHD common problem occur transplant despite use standard immune suppressive medication ( call sirolimus tacrolimus ) . GVHD result skin rash , nausea , vomit , diarrhea , liver damage . Severe GVHD life-threatening . In study , investigator add medication call pacritinib combination sirolimus tacrolimus see approach effectively prevent GVHD . Pacritinib medicine use treat disease bone marrow call myelofibrosis Pacritinib turn switch cell call Janus Kinase 2 ( JAK2 ) . Pacritinib investigational medicine use several clinical trial FDA approve . JAK2 important regulator inflammation . This inflammation think contribute GVHD . Pacritinib able turn inflammation inhibit JAK2 . Research show block JAK2 prevents GVHD mouse also reduce severe GVHD transplant patient . Doctors Moffitt identify inflammation JAK2 important cause GVHD , present well patient develop GVHD symptom . This trial study well pacritinib turn inflammation transplant prevents GVHD add standard medicine . Pacritinib begin day participant 's transplant ( Day 0 ) continue 70 day transplant . Sirolimus give day transplant continue daily least one year . Tacrolimus begin 3 day transplant give least 50 day .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Must available 8/8 HLAA , B , C , DRB1 matchedrelated unrelated donor allogeneic hematopoietic peripheral blood stem cell graft . Signed informed consent . Acute myeloid leukemia , myelodysplasia , acute lymphoblastic leukemia , chronic myeloid leukemia , chronic lymphocytic leukemia , myeloproliferative neoplasm , Hodgkin lymphoma , nonHodgkin lymphoma require match allogeneic hematopoietic stem cell transplantation ( HSCT ) . Acute Leukemia ( AML ALL ) must complete remission define : &lt; 5 % marrow blast morphologic evidence leukemia , peripheral blast , marrow &gt; 20 % cellular , peripheral absolute neutrophil count &gt; 1000/uL ( platelet recovery require ) . Myelodysplasia ( MDS ) chronic myeloid leukemia ( CML ) : Must &lt; 5 % marrow blast . Myeloproliferative neoplasm ( MPN ) : Must &lt; 5 % peripheral / marrow blast . Note : Prior use JAK2 inhibitor allow 4 week day 0 alloHCT . Hodgkin nonHodgkin lymphoma : Must chemosensitive disease . Adequate vital organ function . Performance status : Karnofsky Performance Status Score â‰¥ 80 % . Ferritin &lt; 2000 ng/ml . Donor Eligibility : Eligible donor include healthy sibling , relative unrelated donor match patient HLAA , B , C , DRB1 high resolution type define Collaborative Trials Network . Active infection control appropriate antimicrobial therapy . History HIV , hepatitis B , active hepatitis C infection . Antithymocyte globulin , alemtuzumab , bortezomib , posttransplant cyclophosphamide part GVHD prophylaxis . Sorror 's comorbidity factor total score &gt; 4 . Any patient anticipating schedule receive tyrosine kinase inhibitor , FLT3 inhibitor , JAK2 inhibitor ( outside study ) postHCT . QTc &gt; 450ms per Fridericia 's correction . Thrombin time ( TT ) , prothrombin time ( PT ) , partial thromboplastin time ( PTT ) &gt; 2x upper limit normal ( ULN ) . Grade 3 high recent ( within past 6 month ) ongoing nonQTc cardiac adverse events/comorbidities . Grade 3 high recent ongoing cardiac dysrhythmias , family history long QT . syndrome , serum potassium &lt; 3.0 mEq/L persistent refractory correction . Grade 3 high recent ongoing bleed event . Symptomatic uncontrolled cardiovascular disease , myocardial infarction severe/unstable angina within past 6 month , New York Heart Association ( NYHA ) Class III IV congestive heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>